GlassScriptPhysician profile
Paul A Adkins
NPI 1972810802
$27,930.94
in general payments reported to CMS, 2019-2025
54 companies · $4,539 in 2025
The $4,539 reported for 2025 was more than what 98% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $11K · 2022: $4,292 · 2023: $5,103 · 2024: $3,237 · 2025: $4,539.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,971 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,282 · Education: $581 · Travel and Lodging: $46.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,970.83 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,282.00 |
| Education | $580.58 |
| Travel and Lodging | $46.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $13,678.45 | 2021-2025 | Ubrelvy, Qulipta, Vraylar |
| Astrazeneca Pharmaceuticals LP | $2,572.11 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $1,473.59 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $1,289.27 | 2021-2025 | Mounjaro, Jardiance, Emgality |
| Bayer Healthcare Pharmaceuticals INC. | $1,083.92 | 2022-2025 | |
| Teva Pharmaceuticals USA, INC. | $992.16 | 2021-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Allergan, INC. | $868.08 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $562.06 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $534.43 | 2021-2025 | Xifaxan, Trulance |
| Amgen INC. | $494.93 | 2021-2025 | Repatha, Otezla, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $450.58 | 2021-2025 | Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $434.09 | 2022-2025 | Caplyta |
| Lundbeck LLC | $428.26 | 2022-2025 | Rexulti |
| Axsome Therapeutics, INC. | $335.07 | 2023-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $250.07 | 2021-2025 | Spravato, Invega Sustenna, Invega Trinza |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Adkins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.